This Acquirers Multiple Stock Is Undervalued, According to Dalio, Greenblatt, And Simons

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

Centene Corp (CNC)

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.

A quick look at the price chart below shows us that the stock is down 15.21% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 9.60 which means that it remains undervalued.

CNC data by YCharts

(Shares)

Cliff Asness – 1,536,581

Israel Englander – 1,346,014

Jim Simons – 670,612

Steve Cohen – 458,457

Lee Ainslie – 384,406

Joel Greenblatt – 200,448

Paul Tudor Jones – 176,713

Ray Dalio – 143,045